ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.

Tanya Dorff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.